CA3238183A1 - Methods of treating sars-cov-2 infection - Google Patents

Methods of treating sars-cov-2 infection Download PDF

Info

Publication number
CA3238183A1
CA3238183A1 CA3238183A CA3238183A CA3238183A1 CA 3238183 A1 CA3238183 A1 CA 3238183A1 CA 3238183 A CA3238183 A CA 3238183A CA 3238183 A CA3238183 A CA 3238183A CA 3238183 A1 CA3238183 A1 CA 3238183A1
Authority
CA
Canada
Prior art keywords
cov
sars
infection
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3238183A
Other languages
English (en)
French (fr)
Inventor
Michelle Miller
Gary Dinneen Ewart
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biotron Ltd
Original Assignee
Biotron Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2021903789A external-priority patent/AU2021903789A0/en
Application filed by Biotron Ltd filed Critical Biotron Ltd
Publication of CA3238183A1 publication Critical patent/CA3238183A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3238183A 2021-11-24 2022-11-24 Methods of treating sars-cov-2 infection Pending CA3238183A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2021903789A AU2021903789A0 (en) 2021-11-24 Methods of treating sars-cov-2 infection
AU2021903789 2021-11-24
PCT/AU2022/051405 WO2023092180A1 (en) 2021-11-24 2022-11-24 Methods of treating sars-cov-2 infection

Publications (1)

Publication Number Publication Date
CA3238183A1 true CA3238183A1 (en) 2023-06-01

Family

ID=86538440

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3238183A Pending CA3238183A1 (en) 2021-11-24 2022-11-24 Methods of treating sars-cov-2 infection

Country Status (8)

Country Link
US (1) US20250009713A1 (https=)
EP (1) EP4436576A4 (https=)
JP (1) JP2024543259A (https=)
KR (1) KR20240110039A (https=)
CN (1) CN118574614A (https=)
AU (1) AU2022399231A1 (https=)
CA (1) CA3238183A1 (https=)
WO (1) WO2023092180A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115260100B (zh) * 2022-08-08 2023-12-12 赛诺瑞生物医药技术(无锡)有限公司 一种用于制备冠状病毒治疗药物的取代酰基胍类化合物和用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ596107A (en) * 2005-06-24 2013-09-27 Biotron Ltd Antiviral compounds and methods
ES2563477T3 (es) * 2007-08-03 2016-03-15 Biotron Limited Composiciones antivirales para tratar la hepatitis C a base de 5-(1-metilpirazol-4-il)2-naftoilguanidina y 2'-C-metiladenosina o 2'-C-metilcitidina
SG11201907034PA (en) * 2017-02-08 2019-08-27 Biotron Ltd Methods of treating influenza
US20220409587A1 (en) * 2019-11-26 2022-12-29 Biotron Limited Methods of treating hiv-1 infection
US11660307B2 (en) * 2020-01-27 2023-05-30 Gilead Sciences, Inc. Methods for treating SARS CoV-2 infections
WO2021207049A1 (en) * 2020-04-06 2021-10-14 Gilead Sciences, Inc. Inhalation formulations of 1'-cyano substituted carbanucleoside analogs

Also Published As

Publication number Publication date
JP2024543259A (ja) 2024-11-20
CN118574614A (zh) 2024-08-30
WO2023092180A1 (en) 2023-06-01
EP4436576A4 (en) 2025-09-17
KR20240110039A (ko) 2024-07-12
EP4436576A1 (en) 2024-10-02
US20250009713A1 (en) 2025-01-09
AU2022399231A1 (en) 2024-05-23

Similar Documents

Publication Publication Date Title
KR102607599B1 (ko) 인플루엔자의 치료 방법
US12167994B2 (en) Vidofludimus for use in the treatment or prevention of viral diseases
CN113262215B (zh) 贝壳杉烷类化合物在制备预防和治疗脓毒症及多器官损伤的药物中的应用
JP2021516219A (ja) ライノウイルス感染症の予防又は治療のための薬物
US20250009713A1 (en) Methods of treating sars-cov-2 infection
WO2022088037A1 (zh) Sirtinol在制备预防和治疗冠状病毒的药物中的应用
JP2019504040A (ja) 中等度〜重度のインフルエンザの処置
WO2022079496A1 (en) A pharmaceutical composition of nitazoxanide, albendazole and pyrantel and method thereof
WO2022088025A1 (zh) 帕比司他在制备预防和治疗冠状病毒的药物中的应用
CA3052503C (en) Methods of treating influenza
CN102670684A (zh) 白薇总皂苷的应用
CN120392755A (zh) 氨来占诺在制备治疗或预防呼吸道合胞病毒感染的药物的应用
HK40062780A (en) Vidofludimus for use in the treatment or prevention of viral diseases
WO2025014360A1 (en) Guanosine nucleotide analogs for use in preventing and/or treating hepatitis e virus infection
CN114432283A (zh) Sirtinol在制备预防和治疗冠状病毒的药物中的应用
CN120324444A (zh) 甘草酸在制备治疗或预防呼吸道合胞病毒感染的药物的应用
HK40017310B (en) Methods of treating influenza
HK40017310A (en) Methods of treating influenza
CN114432303A (zh) 帕比司他在制备预防和治疗冠状病毒的药物中的应用
CN105982889A (zh) 抗流感病毒的药物组合物及其应用

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - SMALL

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241119

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241119

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241119

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - SMALL

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241120

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241120

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241120

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - SMALL

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251110

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251110